(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Supplementation with cholecalciferol 1,000 IU/day during pregnancy is associated with greater offspring bone mineral density ...

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...

HEALTH LITERACY: Understanding osteoporosis: Causes, risk factors, and preventive strategies for bone health ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Lung transplant patients should undergo annual bone health screenings using dual-energy X-ray absorptiometry for the first ...

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...

Research indicates that vitamin D supplementation during pregnancy positively impacts children's bone health and lean mass, ...

Investigators used 3-dimensional quantitative computed tomography to more accurately assess patients’ bone mineral density.

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...